Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.

Détails

Ressource 1Télécharger: REF.pdf (369.80 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_044E24F585FB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Périodique
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo
Auteur⸱e⸱s
Martin S.D., Coukos G., Holt R.A., Nelson B.H.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
26
Numéro
12
Pages
2367-2374
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Owing to recent advances in genomic technologies, personalized oncology is poised to fundamentally alter cancer therapy. In this paradigm, the mutational and transcriptional profiles of tumors are assessed, and personalized treatments are designed based on the specific molecular abnormalities relevant to each patient's cancer. To date, such approaches have yielded impressive clinical responses in some patients. However, a major limitation of this strategy has also been revealed: the vast majority of tumor mutations are not targetable by current pharmacological approaches. Immunotherapy offers a promising alternative to exploit tumor mutations as targets for clinical intervention. Mutated proteins can give rise to novel antigens (called neoantigens) that are recognized with high specificity by patient T cells. Indeed, neoantigen-specific T cells have been shown to underlie clinical responses to many standard treatments and immunotherapeutic interventions. Moreover, studies in mouse models targeting neoantigens, and early results from clinical trials, have established proof of concept for personalized immunotherapies targeting next-generation sequencing identified neoantigens. Here, we review basic immunological principles related to T-cell recognition of neoantigens, and we examine recent studies that use genomic data to design personalized immunotherapies. We discuss the opportunities and challenges that lie ahead on the road to improving patient outcomes by incorporating immunotherapy into the paradigm of personalized oncology.
Mots-clé
Animals, Cancer Vaccines/administration & dosage, Genomics/methods, Genomics/trends, Humans, Immunotherapy/methods, Immunotherapy/trends, Neoplasms/immunology, Neoplasms/therapy, Precision Medicine/methods, Precision Medicine/trends, T-Lymphocytes/immunology
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/01/2016 17:31
Dernière modification de la notice
14/02/2022 7:53
Données d'usage